SUPPLEMENTAL FIGURES
. Targeted sequencing methods exhibit lower levels of mouse contamination. Refer to Experimental Procedures. A-B. Bar charts displaying either the raw number or proportion of reads classified by Xenome as confidently 'Human' or 'Mouse,' or as 'Both', 'Neither', or 'Ambiguous' for WGS (n=9), WES (n=16), or RNAseq (n=16) PDX samples. C-D. Distribution of the raw number or proportion of reads in each data type associated with each Xenome class. A. This waterfall plot shows recurrently mutated genes across the cohort of primary tumors and paired xenografts. The bar chart across the top shows the total number of nonsilent mutations identified across each case-matched PDX/tumor. Bars are filled to indicate the number of mutations detected in both tumor and PDX ('Common') or only one sample ('Tumor Only' or 'PDX Only'). The waterfall plot indicates the type of mutation detected in each gene (y-axis) for each sample (x-axis). Borders around tiles indicate whether the mutation was only detected in either the tumor or PDX ('Tumor Only' or 'PDX Only'). The horizontal bar chart on the left indicates the percentage of the cohort containing mutations in the indicated gene. B. Median absolute copy number was calculated across large chromosomal segments, and large copy number alterations were called across the genome. Colored tiles indicate the patient-associated samples. Within each row, the tumor is on the top and the xenograft is on the bottom. C. Genes commonly altered at the copy number level in HNSCC were analyzed with 100kb windows on either ends of the gene. Red rectangles correspond to the genomic positions of the indicated gene. Point color corresponds to sample, and copy neutral samples are indicated. Copy number is indicated by absolute copy number on the y-axis, and only segments with median copy number >3 or <1.5 are indicated by color (according to sample source). The horizontal dotted line at y=2 indicates copy neutral status. 
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES
Xenoengraftment procedures
Tumor biopsies were obtained from patients and and maintained in sterile Dulbecco Modified Eagle's medium containing 10% Fetal Calf Serum (FCS) and 1% amphotericin. Biopsies were sectioned using razor blades into four separate pieces for the following purposes: (1) formalin fixation for storage and immunohistochemical analysis (2) flash freezing in liquid nitrogen for DNA and RNA extraction, (3) slow freezing in FCS containing 10% dimethyl sulfoxide (DMSO) for downstream experiments, and (4) immediate transplantation into mice for xenograft generation.
Within one hour of acquisition, fresh tumor was immediately minced into approximately 16 pieces, ranging in size from 2-8 mm3, and transferred on ice to the animal facility. 6-8 week old NOD-scid ILRgnull (NSG) mice (Jackson Laboratory, Bar Harbor, ME) were anesthetized, shaved, and four small incisions were made, one on each quadrant of the flank. Tumor pieces were then saturated with Matrigel (Corning, Tewksbury, MA), and four pieces were transferred subcutaneously into each quadrant using sterile forceps.
Mice were maintained on sterile water containing sulfamethoxazole (280 ug/mL) and trimethoprim (56 ug/mL) for one month after injection and monitored twice weekly for tumor growth. Successful establishment was defined as progressive tumor growth and tumors were harvested at approximately 2 cm3 tumor volume. Xenografts were resected and divided in the same manner as the primary tumors and were named the "P0" generation. In some cases, P0 generation tumors were slow-frozen in FCS+10% DMSO and thawed for subsequent engraftment of the P1 generation.
Trametinib treatment of engrafted mice
Trametinib (Selleckchem, Houston, TX) was dissolved in DMSO (10 mg/mL), and further diluted into sterile water containing 0.5% w/v hypromellose (Sigma-Aldrich, St. Louis, MO) and 2% v/v Tween-80 (Sigma-Aldrich, St. Louis, MO) to a concentration of 0.3 mg/mL (Banks et al., 2015) . Mice bearing successfully engrafted OCSCC tumors were treated with daily oral gavage with either trametinib (3 mg/kg), or vehicle alone beginning 7 days after implantation. Tumor dimensions were measured daily.
Sequencing methods
Library construction and sequencing were performed as previously described with a few exceptions described below (Griffith et al., 2015a) . Single indexed libraries were constructed according to the manufacturer's recommendations using the Illumina TruSeq Nano Kit (Illumina Inc, San Diego, CA) for whole genome sequencing (WGS) on the Illumina HiSeq X (2x150 bp reads). Genomic DNA was fragmented using the Covaris E210 DNA Sonicator (Covaris, WoBurn, MA). Dual indexed whole exome sequencing (WES) libraries were constructed/pooled according to the manufacturer's recommendations using one of three kits/approaches: (1) the Paired-End Sample Prep Kit (Illumina Inc, San Diego, CA) for sequencing on the HiSeq 2500 (2x125 bp reads) (2) Kapa Auto Illumina (Kapa Biosystems, Woburn, MA) for sequencing on the HiSeq 2500 V4 1Tb (2x125 bp reads) and (3) Kapa Auto Illumina (Kapa Biosystems, Woburn, MA) for sequencing on the HiSeq 4000 (2x150 bp reads). Samples were pooled and captured using one of four capture reagents: (1 
Somatic event detection
The Genome Modeling System (GMS) was used for all analysis, including the somatic variant detection and RNA-seq analysis (Griffith et al., 2015b) . Single nucleotide variants (SNVs) were detected by taking the union of VarScan2 v2.3.6 , Strelka v1.0.11 (Saunders et al., 2012) , Mutect v1.1.4 (Cibulskis et al., 2013) , and SomaticSniper v1.0.4 , and filtered using Samtools r982 (Li et al., 2009) ([mpileup -BuDS] filtered by var-filter-snv v1 then false-positive-vcf v1). Small insertions and deletions (indels) were detected by GATK Somatic Indel Detector (v5336) (McKenna et al., 2010) , VarScan2, Strelka, and Mutect. Variants were annotated by the GMS transcript variant annotator against Ensembl v74 and compared to the database of curated mutations (DoCM) (Ainscough et al., 2016; Chen et al., 2016) and COSMIC mutations (Forbes et al., 2011) . All SNVs and indels were manually reviewed for removal of false positives according to standard procedures (Barnell et al., 2018) .
Analysis of published expression data and random forest classification. 728 genes were previously used to define four molecular subtypes of HNSCC using this gene expression dataset (Walter et al., 2013) . These 728 genes (HGNC symbols) mapped to 797 gene identifiers in the Ensembl v90 database. The union of Ensembl gene identifiers was taken across three experiments -Walter et al., the TCGA HNSCC dataset (Cancer Genome Atlas Network, 2015) , and this study (hereafter referred to as WUSM) -to produce a final list of 638 Ensembl gene IDs. The microarray probe-level intensity files (containing log2-transformed, normexp background-corrected, loess-normalized values) from Walter et al. (GSE39366, n=138) were gene median-normalized (Walter et al., 2013) . Gene expression data (FPKM) from the TCGA HNSCC cohort (n=277) was log2-transformed and gene median-normalized (Cancer Genome Atlas Network, 2015) . The randomForest R package v.4.6-12 was used to build a classifier using the 638 genes and the 138 samples from the Walter et al. dataset (GSE39366) based upon their previously reported molecular subtypes . The classifier was defined using 1,001 trees and downsampling to the minimum sample size per molecular subtype (n=29). Model performance was validated using the randomForest package by applying the classifier to the TCGA dataset and comparing predictions to the previously reported molecular subtypes. Tumor RNA expression (FPKM) reported in this study (WUSM; n=16) was log2-transformed and gene median-normalized, and molecular subtypes were predicted by applying the classifier to these expression values.
Genes associated with cancer-associated fibroblasts (CAFs) were used to compare classified mesenchymal tumors with others, based upon the transformed/gene median-normalized expression values within each dataset (Walter et al., TCGA, WUSM) . Puram et al. showed that expression of 449 genes can be used to describe a signature associated with cancer-associated fibroblasts (CAFs) that defines the mesenchymal molecular subtype of head and neck cancers (Puram et al., 2017) . These 449 genes mapped to 412 Ensembl gene identifiers assessed in the Walter et al., TCGA, and WUSM datasets. The 412 genes associated with CAF expression signatures were gene-median centered (GMC) with respect to each dataset, and then these 412 genes were summarized per sample by the median GMC value (denoted as 'CAF signature' in Figure 5 ).
